Healthcare
Senti Biosciences, Inc.(SNTI)
Live Price
Offline$0.932
-2.00% today
1Y Change
-53.17%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $30.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +76.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Senti Biosciences, Inc. (SNTI) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.93 and down 53.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +76.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +76.2%, free cash flow -5.4% with operating margin -289668.2% and ROIC -149.7%. Valuation already assumes a fairly strong business story at price/sales 1218.9. Stock Foundry combines SNTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-289668.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +76.2%, while operating margin sits near -289668.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +1.8% | +1.7% | +2.2% |
2026 Mar 27, 2026 | +11.6% | -2.3% | +15.4% | +34.2% |
2025 Nov 13, 2025 | -16.9% | -10.1% | +1.1% | -26.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNTI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNTI Max Drawdown
-67.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNTI and SPY.
Company Overview
Senti Biosciences, Inc.
NASDAQ Global Market
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
- Leadership
- Timothy K. Lu
- IPO Date
- May 26, 2021
- Employees
- 34
- Street Address
- 2 Corporate Drive
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- (650) 382-3281
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1218.9
- Price/Book
- 4.1
Growth
- Revenue
- 0.0%
- EPS
- +76.2%
- Free Cash Flow
- -5.4%
Profitability
- Gross Margin
- -14777.3%
- Operating Margin
- -289668.2%
- Net Margin
- -279263.6%
- ROE
- -322.4%
- ROIC
- -149.7%
Balance Sheet
- Debt/Equity
- 5.17
- Current Ratio
- 1.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.